Shots:
- ImmunityBio’s Anktiva + Bacillus Calmette-Guérin (BCG) has received the US FDA’s approval to treat BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) and with/without papillary tumors. The US availability is anticipated by mid-May 2024
- The approval & BTD was based on the study of 77 evaluable patients depicting a CR rate 62% with the confidence interval of 73% and DoR >47mos, as of Nov 2023
- The DoR & subsequent mDoR evaluation is in progress. Among 58% CR patients, DoR is ≥12mos. & 40% had ≥24mos. DoR
Ref: ImmunityBio | Image: ImmunityBio | Press Release
Related News:- Basilea’s Zevtera Receives the US FDA’s Approval for Staphylococcus aureus Bloodstream Infections
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
